Previous 10 | Next 10 |
Normally, companies with share prices lower than $5 -- commonly called penny stocks -- wouldn't even be worth a glance. These types of equities tend to suffer from poor fundamentals, an exorbitant number of outstanding shares, and shaky management. Making matters worse, penny stocks also tend to...
April 23, 2020 Palm Beach, FL – April 23, 2020 – The Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects...
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that it has appointed John H. Johnson to its Board of Directors. Mr. Johnson’s career cove...
Verastem, Inc. (NASDAQ: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that in light of public health and safety precautions related to COVID-19, including restriction...
Shares of Verastem Oncology (NASDAQ: VSTM) , a biotechnology company developing new cancer drugs, are on the rise again after the company announced an upcoming conference call. Investors excited to hear what management will have to say about an investigator-initiated study (i.e., on...
Verastem Oncology (NASDAQ: VSTM ) will host an investor conference call on Monday, April 27 at 8:00 AM ET, to discuss the clinical data from the ongoing investigator-initiated study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibit...
Conference Call to Discuss Preliminary Clinical Data Being Presented at the American Association for Cancer Research 2020 Virtual Annual Meeting I Conference Call Scheduled for Monday, April 27, 2020 at 8:00 AM ET Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a b...
Preliminary Results from Dose Escalation Portion and Expansion Cohorts Investigating VS-6766 in Combination with Defactinib in Patients with KRAS Mutant Advanced Solid Tumors to be Highlighted in a Virtual Poster Presentation Management to Host Investor Conference Call Following the Vi...
Verastem Oncology ( VSTM ) was founded in 2010 and is based in the Boston area (Needham). The company has an FDA-approved product, Copiktra. The stock was beaten down since the drug got approved. Management announced a change in its strategy and decided to shift its focus to the newly acquir...
The government's $2 trillion emergency relief package caused shares to skyrocket this week; however, the helicopter-Ben style package may inadequately address mid-term economic instability. If so, then this week's rapid run-up could be a short-term sugar high that wears off in April once disma...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...